Tuesday, June 30, 2015

Another diabetes drug in trouble?

The US Food and Drug Administration announced Friday it has begun a safety review of the diabetes drug Actos after preliminary results of an ongoing study showed the medication might increase the risk of bladder cancer in some patients.

Another diabetes drug in trouble?

0 comments

The US Food and Drug Administration announced Friday it has begun a safety review of the diabetes drug Actos after preliminary results of an ongoing study showed the medication might increase the risk of bladder cancer in some patients.

Actos, also known as pioglitazone, is made by Takeda Pharmaceuticals. It has been in the news lately as the safer alternative to GlaxoSmithKline’s Avandia, or rosiglitazone, which has been linked to increased risk of heart failure, heart attacks and strokes.

The FDA announced the review after getting five-years of data from a 10-year observational study of Actos by Takeda. The results showed no overall increased risk of bladder cancer.

“However, there was an increased risk of bladder cancer in patients with the longest exposure to Actos and in those with the highest cumulative dose of the drug,” the FDA stated. “Patients should talk to their health care professional if they have concerns about Actos. They should not stop taking the drug unless told to do so by their health care professional.”

To check out more Check Up items go to www.philly.com/checkup.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Check Up covers regional health news and a wide array of healthcare topics from pharmaceutical happenings to patient safety. Read about some of our bloggers here.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on Philly.com:
letter icon Newsletter